PCRX earnings call for the period ending March 31, 2019.
News & Analysis: Pacira BioSciences
The small drugmaker posted record sales for its flagship drug in the first quarter.
Heron's pain is Pacira's gain.
PCRX earnings call for the period ending December 31, 2018.
The company's shares are rallying today on an analyst upgrade.
Find out how these stocks escaped the carnage on Wall Street.
Despite a mixed third-quarter report, Pacira topped Wall Street's expectations where it counts.
Disappointing late-stage trial data is dashing investor optimism.
You'd struggle to find faster-growing small-cap stocks.
Exparel's ability to reduce post-operative pain lowers the need for opioids.